Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs. The Company's lead development programs include eRapa, under development for Familial Adenomatous Polyposis and Non-Muscle Invasive Blader Cancer: tolimidone, under development as a for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications. July ...

July 16, 2024 Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announces progress on initiation of a Phase 2a study of tolimidone in Type 1 diabetes ("T1D"). Commenting, Stephen Stamp, CEO and CFO of Biodexa said: "We are excited to initiate our clinical program in Type 1 diabetes with the University of Alberta and build on the extensive tolim ...

Biodexa Pharmaceuticals (NASDAQ:BDRX) stock is rocketing higher on Thursday after announcing additional positive results from a Phase 2 clinical trial. According to the company, results from its study of eRapa are going well. This is its treatment candidate for Familial Adenomatous Polyposis (FAP). That's a mostly inherited condition that increases the risk of developing colorectal cancer. Results from 12 months of study show a median 17% decrease in overall polyp burden. It also showed an overall non-progr ...

Biodexa Pharmaceuticals PLC After Only Two Infusions and Two Patients at Optimal Dose, Median Overall Survival Across all Patients was 16.5 Months (vs 10.0 Months in Historical Reference Cohort) (DATELINE) JULY 2 -- Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announces data from a Phase 1 study of MTX110 in Diffuse M ...

June 24, 2024 Biodexa Announces Positive Phase 2 Clinical Trial Results of eRapa™ at 12 months in Familial Adenomatous Polyposis (FAP) Median Decrease in Overall Polyp Burden at 12 Months of 17% Cohort 2 Non-progression Rate at 12 months of 81% and Median Decrease in Poly Burden of 29% Informs Phase 3 Dosage Regimen (DATELINE) JUNE 24 -- Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative ...

Core Insights - Biodexa Pharmaceuticals PLC announced promising results from a Phase 2 clinical trial of eRapa™ for Familial Adenomatous Polyposis (FAP), showing a 75% non-progression rate at 12 months and a median reduction in polyp burden of 17% [1][4][5] Group 1: Clinical Trial Results - The Phase 2 study reported that 21 out of 28 patients (75%) were non-progressors at 12 months, with a median reduction in polyp burden of 17% [4][5] - In Cohort 2, 89% of patients were non-progressors with a median reduction in polyp burden of 29% [5][12] - The study was partially funded by a $3 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT) [2] Group 2: Future Studies and Funding - A Phase 3 registrational study is planned, which will be a double-blind placebo-controlled trial involving approximately 140 high-risk patients [6] - The Phase 3 study is supported by a $17 million grant from CPRIT [2][6] - The primary endpoint for the Phase 3 study will focus on the first progression-free survival event, including major surgery and diagnosis of high-grade dysplasia or cancer [6] Group 3: Drug Information - eRapa is a proprietary oral formulation of rapamycin, an mTOR inhibitor, designed to improve bioavailability and reduce toxicity compared to existing forms of rapamycin [7][19] - eRapa has received Orphan Designation in the US, with plans to seek similar designation in Europe [15] Group 4: Company Overview - Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing innovative treatments for diseases with unmet medical needs, including eRapa for FAP and other products for different indications [23][25]

("Biodexa" or the "Company") About Biodexa Pharmaceuticals PLC MTX110 is a solubilised formulation of the histone deacetylase (HDAC) inhibitor, panobinostat. This proprietary formulation enables delivery of the product via convection-enhanced delivery (CED) at chemotherapeutic doses directly to the site of the tumor, by-passing the blood-brain barrier and potentially avoiding systemic toxicity. Reference should be made to those documents that Biodexa shall file from time to time or announcements that may be ...

For more information, please contact: Biodexa Pharmaceuticals PLC Stephen Stamp, CEO, CFO June 10, 2024 Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announces that 12 month data of a Phase 2 clinical trial of eRapa in Familial Adenomatous Polyposis ("FAP") are to be presented at the prestigious biennial InSIGHT 2024 meeting in Barcelona, Spain o ...

June 10, 2024 Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announces that 12 month data of a Phase 2 clinical trial of eRapa in Familial Adenomatous Polyposis ("FAP") are to be presented at the prestigious biennial InSIGHT 2024 meeting in Barcelona, Spain on June 22, 2024. Carol Burke, MD, ...

May 22, 2024 Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises Proceeds Cover Year 1 eRapa Phase 3 Obligations, Unlocking Twice that Amount in Non-dilutive Grant Funding Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announces $7 million of gross proceeds from the exercis ...